0.1108
3.45%
0.0037
After Hours:
.11
-0.0008
-0.72%
Cns Pharmaceuticals Inc stock is traded at $0.1108, with a volume of 3.33M.
It is up +3.45% in the last 24 hours and down -7.28% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$0.1071
Open:
$0.1045
24h Volume:
3.33M
Relative Volume:
0.24
Market Cap:
$4.51M
Revenue:
-
Net Income/Loss:
$-18.61M
P/E Ratio:
-0.011
EPS:
-10.05
Net Cash Flow:
$-13.91M
1W Performance:
-19.54%
1M Performance:
-7.28%
6M Performance:
-99.00%
1Y Performance:
-99.89%
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire
CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World
CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com UK
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - AccessWire
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content
CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia
CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com
CNS Pharmaceuticals secures $3 million in registered direct offering By Investing.com - Investing.com UK
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - AccessWire
CNS Pharmaceuticals faces NASDAQ delisting over price rule - Investing.com
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.12, Up by 0.77 - The Dwinnex
Can you still get a good price for Cns Pharmaceuticals Inc (CNSP) Shares at this point? - US Post News
CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates In Virtual Investor KOL Connect Segment - Barchart
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum - MSN
It is Poised to be a Bull Market for Cns Pharmaceuticals Inc (CNSP) - SETE News
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - BioSpace
Ladenburg Thalmann gives a Neutral recommendation for Cns Pharmaceuticals Inc (CNSP) - Knox Daily
Cns Pharmaceuticals Inc (CNSP) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC - StockTitan
A stock that deserves closer examination: Cns Pharmaceuticals Inc (CNSP) - US Post News
Ratio Examination: Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - The Manila Times
Wall Street analysts’ outlook for Cns Pharmaceuticals Inc (CNSP) - SETE News
Cns Pharmaceuticals Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Titan Medical Inc (TMD-T) QuotePress Release - The Globe and Mail
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 - The Manila Times
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - ForexTV.com
Cns Pharmaceuticals Inc (CNSP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Examining Cns Pharmaceuticals Inc (CNSP) stock is warranted - US Post News
CNS Therapeutics Market 2024 Share, Growth Forecast and Industry Outlook 2032 | Eli Lilly and Co. - 대구포스트
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
A new trading data show Cns Pharmaceuticals Inc (CNSP) is showing positive returns. - SETE News
Do investors need to be concerned about Cns Pharmaceuticals Inc (CNSP)? - US Post News
CNS (Central Nervous System) Therapeutics Market 2024 Size, Status and Global Outlook 2031 - Newstrail
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum - AccessWire
Ratio Review: Analyzing Cns Pharmaceuticals Inc (CNSP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology
Cns Pharmaceuticals Inc (CNSP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Brain cancer drugmaker CNS Pharma warns of possible Nasdaq delisting - Kursiv Media
An analyst sees good growth prospects for Cns Pharmaceuticals Inc (CNSP) - SETE News
What was Cns Pharmaceuticals Inc (CNSP)’s performance in the last session? - US Post News
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.15, Down by -0.54 - The Dwinnex
CNS Pharmaceuticals regains NASDAQ compliance - Investing.com
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement - AccessWire
Such Is The Power Of Cns Pharmaceuticals Inc (NASDAQ: CNSP) - Stocks Register
CNS Pharmaceuticals (NASDAQ:CNSP) Upgraded to “Buy” at Maxim Group - Defense World
CNSP Stock: Exploring Cns Pharmaceuticals Inc’s Growth - The InvestChronicle
Maxim raises CNS Pharmaceuticals to buy, cites improved financial position - Investing.com
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):